Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

SpringWorks Therapeutics (SWTX)

SpringWorks Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SWTX
DateTimeSourceHeadlineSymbolCompany
23/05/202422:13GlobeNewswire Inc.SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:SWTXSpringWorks Therapeutics Inc
17/05/202421:53Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SWTXSpringWorks Therapeutics Inc
08/05/202412:00GlobeNewswire Inc.SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care ConferenceNASDAQ:SWTXSpringWorks Therapeutics Inc
02/05/202411:30GlobeNewswire Inc.SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business UpdatesNASDAQ:SWTXSpringWorks Therapeutics Inc
24/04/202418:31GlobeNewswire Inc.SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:SWTXSpringWorks Therapeutics Inc
18/04/202412:00GlobeNewswire Inc.SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024NASDAQ:SWTXSpringWorks Therapeutics Inc
04/03/202411:30GlobeNewswire Inc.SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PNNASDAQ:SWTXSpringWorks Therapeutics Inc
01/03/202422:16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SWTXSpringWorks Therapeutics Inc
29/02/202413:30GlobeNewswire Inc.SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid TumorsNASDAQ:SWTXSpringWorks Therapeutics Inc
27/02/202413:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SWTXSpringWorks Therapeutics Inc
27/02/202413:23Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SWTXSpringWorks Therapeutics Inc
27/02/202412:29Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SWTXSpringWorks Therapeutics Inc
27/02/202411:51Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:SWTXSpringWorks Therapeutics Inc
27/02/202411:44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SWTXSpringWorks Therapeutics Inc
27/02/202411:30GlobeNewswire Inc.SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business UpdatesNASDAQ:SWTXSpringWorks Therapeutics Inc
22/02/202412:00GlobeNewswire Inc.SpringWorks Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:SWTXSpringWorks Therapeutics Inc
20/02/202423:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SWTXSpringWorks Therapeutics Inc
16/02/202418:09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SWTXSpringWorks Therapeutics Inc
14/02/202413:56Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SWTXSpringWorks Therapeutics Inc
06/02/202402:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SWTXSpringWorks Therapeutics Inc
06/02/202402:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SWTXSpringWorks Therapeutics Inc
02/02/202421:38Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SWTXSpringWorks Therapeutics Inc
02/02/202421:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SWTXSpringWorks Therapeutics Inc
31/01/202412:00GlobeNewswire Inc.SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:SWTXSpringWorks Therapeutics Inc
09/01/202402:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SWTXSpringWorks Therapeutics Inc
09/01/202402:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SWTXSpringWorks Therapeutics Inc
09/01/202402:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SWTXSpringWorks Therapeutics Inc
09/01/202402:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SWTXSpringWorks Therapeutics Inc
09/01/202402:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SWTXSpringWorks Therapeutics Inc
09/01/202402:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SWTXSpringWorks Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SWTX